BRAF and melanoma: PGC1A and MITF are a notorious pair implicated in overcoming melanoma’s glycolytic dependence [48,69] and in development of rapid resistance to BRAF-inhibitor therapy [43,47], a cornerstone in recent melanoma therapeutics [70], and are currently in clinical trials as an adjuvant in melanoma immunotherapy [71].